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Abstract
Cycling at faster pedaling rates leads to symptomatic improvement in patients with
Parkinson’s disease (PD). However, these patients show inter-limb asymmetry in pedaling power
when cycling at their slow self-selected cadence. The effects of faster pedaling cadence on
symmetry of effort between limbs is unknown. We compared the effect of pedaling cadence on
symmetry of crank power output in individuals with PD versus healthy controls. In this case
series, two participants with PD and two healthy controls performed 3-minute bouts of stationary
cycling at three cadences (50, 65, 80 rpm) at 60W and self-selected workload. Power output
contribution of each limb towards total crank power output was computed over 60 crank cycles
from the effective component of pedal force, which was perpendicular to the crank arm.
Although no statistical analysis was performed for this case series, the data across the
experimental conditions showed that individuals with PD demonstrated substantial interlimb
asymmetry in power output (35-154%) compared to healthy controls (1-34%). There was no
clear trend for the effect of pedaling cadence in participants with PD and healthy controls. Two
patients with PD and one healthy control participant showed an increase in asymmetry with
increase in pedaling cadence. In conclusion, participants with PD demonstrate large interlimb
asymmetries in power output compared to healthy controls and this interlimb asymmetry is not
systematically affected by pedaling cadence.
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Chapter I

Introduction
Parkinson’s disease (PD) is a common progressive neuromuscular condition affecting
more than 10 million individuals worldwide 1-3 and costs the healthcare system in the United
States 14 billion dollars annually 4. In patients with PD, degeneration of the dopaminergic
neurons within the substantia nigra leads to substantial reduction in dopamine production 5-6,
resulting in symptoms such as resting tremors, bradykinesia or akinesia, rigidity, and postural
imbalance 7-11. These symptoms adversely affect the ability of these patients to perform activities
of daily living such as maintaining balance and walking. In addition, these clinical features in
patients with PD are generally more pronounced on one side compared to the other, thereby
leading to asymmetry in performing motor tasks, such as walking and cycling 12-13.
Cycling is a commonly prescribed mode of neurorehabilitation for patients with PD 9, 1314

. Generally, patients with PD are prescribed stationary cycling at high cadences (i.e. 80-90 rpm)

three times per week with sessions ranging from 30-60 minutes 9, 15-16. Post-cycling sessions,
patients experience immediate and long-term improvements, such as decreases in resting tremor,
bradykinesia, and rigidity 9, 17-18, and enhancement in executive function 19. Cycling cadence is a
critical variable for effectiveness of pedaling as an intervention for patients with PD. Several
studies have shown that symptomatic improvement is only observed at faster, and not slower or
preferred cadences in patients with PD 9, 14, 17, 20. Researchers have speculated that cycling at
faster cadences alleviates symptoms of PD by promoting changes in neural drive by increasing
both motor output and sensory input 14, 16. More specifically, it is suggested that increasing
cadence improves the rhythmic pattern generation that is required in lower extremity
coordination 13.

Penko et al. 13 found that individuals with PD are asymmetrical when pedaling at their
self-selected cadences. Specifically, these individuals exerted lesser power with their more
affected leg and compensated by exerting greater power with their less affected side. Generally,
self-selected cadences of patients with PD were low (59 ± 13 rpm) 9, 14, 16-17, 21, whereas
symptomatic improvements were observed at faster pedaling cadences (80-90 rpm) 9, 14, 16-17, 21.
Previous research in healthy subjects has shown that pedaling at faster cadences reduces
asymmetry in power output. However, no previous research has investigated whether asymmetry
of power output between lower limbs in cycling changes when pedaling at faster, compared to
slower, cadences in patients with PD. As with healthy subjects, pedaling at faster cadences could
also reduce interlimb asymmetry in power output for patients with PD. However, this hypothesis
has not yet been tested. Interlimb asymmetry in pedaling power would place asymmetrical
stresses on the lower extremity joints on each side 22-23. By reducing interlimb asymmetry in
cycling, effectiveness of pedaling could potentially be improved for rehabilitation of patients
with PD.
The purpose of this study was to examine the effects of pedaling cadence on interlimb
asymmetry in crank power output in patients with PD compared to healthy controls. We
hypothesized that: 1) interlimb asymmetry in power output would be greater for patients with PD
compared to healthy controls, and; 2) interlimb asymmetry in power output would decrease at
faster cadences.
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Chapter II
Methods
Study Design
In this cross-sectional, case-controlled study, differences in interlimb asymmetry in crank
power outputs at different cadences were assessed during low-intensity stationary cycling
between patients with PD and age-and-sex matched control subjects. All experimental data were
collected in a single data collection session. The Western Washington University Institutional
Review Board approved the study, and all participants gave written informed consent before
participating.
Participants
Eight individuals with idiopathic PD and eight age-and-sex matched healthy controls
were recruited from the surrounding community. Sample size was calculated using GPower 3.1
software based on index of asymmetry data reported by Penko et al.13. A total sample size of 16
participants (8 per group) was needed to achieve a statistical power of 0.8 to detect a large effect
size (Cohen’s f = 0.53) 24 for group main effects at an alpha level of 0.05.
Participants with PD visited their neurologist to get screened before visiting the lab.
These individuals were also assessed by a local neurologist within four weeks of their testing
day. The Movement Disorders Society’s revision of Unified Parkinson’s Disease Rating Scale
(UPDRS) was utilized while the participants were “off” anti-parkinsonian medication for at least
twelve hours prior to examination, and only individuals with Hoehn and Yahr stage II-III were
eligible to participate 13. UPDRS is a reliable and valid test to assess the severity of Parkinson’s
disease 25-26. This scale was used to determine which lower extremity was more affected, based
on UPDRS motor examination of tremor, rigidity, and leg agility score on each side. These tests
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were scored on a scale from 0-4. A score of 0 indicates a normal, unaffected individual, where a
score of 4 indicates a high severity of PD 15. These data were used to identify the limb that was
more affected by PD.
All of the participants completed a health history and physical health questionnaire to
screen for exclusion criteria and obtain information about their current physical activity status
and exercise experience. Exclusion criteria included any muscular, orthopedic, other neurologic,
and/or cardiovascular disorders that limited an individual’s ability to pedal on an ergometer at
low to moderate intensities for more than thirty minutes. The Western Washington University
Institutional Review Board approved the study, and all participants gave written informed
consent before participating.
Instrumentation
All pedaling trials were conducted on an electronically braked Velotron Dynafit cycle
ergometer (Racer-Mate Inc., Seattle, WA) which is shown to be accurate and reliable for
measuring power output during cycling 27-28. Power output of each leg was determined using an
instrumented force pedal system (Sensix, Poitiers, France), which synchronously measures pedal
forces in all planes of motion via orthogonal strain gauges, and pedal and crank orientation via
optical encoders. Prior to arrival of participants, the calibration of the Velotron ergometer was
verified by performing the Accuwatt calibration check test (Racer-Mate Inc., Seattle, WA) and
instrumented force pedals were initialized to ensure they were calibrated accurately with respect
to manufacturer settings.
Procedures
In a single test session, participants completed six three-minute pedaling trials at
cadences of 50, 65, and 80 rpm at an experimentally controlled power output (i.e. 60 W) 13, and
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self-selected power output 9, 14, 16 in a random order. These chosen cadences fell within the range
of self-selected cadences (i.e. 50-70 rpm) 9, 14, 16 and therapeutically prescribed cadences (i.e. 7590 rpm) 9, 14, 16, 21 of individuals with PD. Subjects were asked to change into comfortable clothes
to cycle in, and shoes provided by the researchers. The subjects’ mass and height were measured
in kilograms and meters, respectively, using a standard balance beam scale with stadiometer.
Subjects then completed a three-minute warm-up at a self-selected resistance and a self-selected
cadence on the Velotron cycle ergometer 13, 15. Three minutes of rest followed the warm-up,
during which participants sat on the cycle ergometer. Following this warm-up, participants
completed three-minute trials at self-selected resistances for the three cadences (50 rpm, 65 rpm,
and 80 rpm). Following the self-selected power output pedaling conditions, participants repeated
the three 3-minute trials of the same cadences at a controlled resistance of 60 W in a random
order. A rest interval of three minutes separated each condition.
During these six cycling conditions, data were synchronously captured for bilateral pedal
forces and orientation, and crank position using instrumented force pedals at a sampling
frequency of 240 Hz during the entire three-minute experimental condition. Verbal
encouragement was provided along with a visual screen (image below) that participants watched
in order to maintain their assigned cadence. Participants finished with a three-minute cool-down
at a self-selected resistance and a self-selected cadence 13, 15.
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Figure 1. Cadence feedback provided via Velotron CS software
Data Analysis
The crank position, pedal orientation, and pedal force data were low pass filtered at 4 Hz
using a fourth order recursive Butterworth filter 22-23, 34. The pedal forces were transposed to the
crank coordinate system using pedal force and orientation, and crank position data using the
Sensix I-Crankset software (Poitiers, France). The anterior-posterior and normal components of
pedal forces were then used to compute resultant sagittal pedal forces. Effective component of
force is the only component of force that creates the angular impulse to rotate the crank. The
effective force was computed as the component of the resultant force perpendicular to the crank
arm using trigonometric methods described in previous studies 29-30. Effective crank torque on
each side for a complete crank cycle was computed as a product of the component of the
effective pedal force and length of crank arm (0.1725 m). The crank power on each side was
computed as a product of effective crank torque and crank angular velocity. The data for crank
power on each side were then averaged over 60 crank cycles.
Based on the average crank power output measured for each limb, the Symmetry Index
(SI) was calculated for each 360-degree crank cycle. The equation to compute symmetry index is
based on previous research 13, 31 and it is as follows:
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𝑆𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝐼𝑛𝑑𝑒𝑥 (𝑆𝐼) = (

𝑈𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑖𝑚𝑏 − 𝐴𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑖𝑚𝑏
)
(𝑈𝑛𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑖𝑚𝑏 + 𝐴𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑖𝑚𝑏)/2

Values from this equation can be used to quantify the magnitude of contribution from each limb.
A positive value indicates a greater contribution from the unaffected limb, while a negative value
indicates a greater contribution from the affected limb 13. This equation can be modified to
evaluate the contribution of left versus right lower extremity contribution, or dominant versus
non-dominant leg power. For the control group, leg dominance was determined by asking which
leg they preferred to use to kick a ball 32-33.
𝐷𝑜𝑚𝑖𝑛𝑎𝑛𝑡 − 𝑁𝑜𝑛𝑑𝑜𝑚𝑖𝑛𝑎𝑛𝑡 𝑙𝑖𝑚𝑏
𝑆𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝐼𝑛𝑑𝑒𝑥 (𝑆𝐼) = (
)
(𝐷𝑜𝑚𝑖𝑛𝑎𝑛𝑡 𝑙𝑖𝑚𝑏 + 𝑁𝑜𝑛𝑑𝑜𝑚𝑖𝑛𝑎𝑛𝑡 𝑙𝑖𝑚𝑏)/2

Statistical analysis
For this case series a statistical analysis was not performed. Descriptive data associated
with the experiment were presented.
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Chapter III
Results
Due to difficulty in recruiting the PD patient population, only data for two individuals
with PD and two age-and sex-matched controls were collected. For this small sample size,
statistical analysis was not conducted. Descriptive statistics of the data collected are presented
below.
Descriptive statistics for each pair of participants (i.e., Participant with PD and control) are
presented below in Table 1.
Table 1. Participant demographic characteristics

Age (years)
Sex
Height (cm)
Mass (kg)

PD
Participant
1
67
female
164
50.90

Control
Participant
1
67
female
165
60.00

PD
Participant
2
70
female
155
44.09

Control
Participant
2
70
female
170
69.10

Average weekly cycling (min)

240

90

180

0

Characteristics

Other regular weekly physical
665
200
240
240
activity (min)
State of PD (Hoehn & Yahr
2-3
NA
2-3
NA
Scale)
Duration of disease (yrs)
6
NA
3
NA
NA = Not applicable.
Each participant’s data relevant to their cycling performance and asymmetry is presented
in the subsequent tables (Tables 2-5). Although the data presented are descriptive in nature, it
shows that participants with PD demonstrated a greater degree of asymmetry in their pedaling
performance. For example, the range of asymmetry index in participants with PD was 35-154%
whereas for the control group, this range was 1-34%. In addition, the degree of asymmetry
increased with pedaling cadence for three of the four participants. In only one healthy control,
cadence did not systematically affect pedaling asymmetry.
8

Table 2. PD participant 1 cycling performance and asymmetry data
Preferred PO
Fixed PO (60 W)
50 rpm
65 rpm
80 rpm
50 rpm
65 rpm
80 rpm
Cadence (rpm)
49.9
64.9
79.6
50.1
65.0
79.9
Total PO (W)
44.2
37.8
42.6
58.4
60.4
68.2
Absolute PO less
34.4
32.5
37.4
43.3
46.1
50.4
affected limb (W)
Absolute PO more
9.8
5.3
5.2
15.1
14.3
17.8
affected limb (W)
Relative PO less
77.8
86.0
88.3
74.1
76.5
74.1
affected limb (%)
Relative PO more
22.2
14.0
11.7
25.9
23.5
25.9
affected limb (%)
Asymmetry Index (%)
111.0
144.2
153.0
96.6
106.0
96.5
Note. PO = Power Output.

Table 3. Control participant 1 cycling performance and asymmetry data
Preferred PO
Fixed PO (60 W)
50 rpm
65 rpm
80 rpm
50 rpm
65 rpm
80 rpm
Cadence (rpm)
50.5
65.7
80.6
50.7
65.2
80.0
Total PO (W)
74.3
79.4
67.6
58.0
59.3
63.1
Absolute PO dominant
39.0
39.5
33.2
31.4
29.4
31.8
limb (W)
Absolute PO non35.4
39.9
34.4
26.7
29.9
31.3
dominant limb (W)
Relative PO dominant
52.4
49.7
48.9
54.0
49.4
50.3
limb (%)
Relative PO non47.6
50.3
51.1
46.0
50.6
49.7
dominant limb (%)
Asymmetry Index (%)
9.4
-1.3
-4.4
16.0
-2.3
1.0
Note. PO = Power Output.
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Table 4. PD participant 2 cycling performance and asymmetry data
Preferred PO
Fixed PO (60 W)
50 rpm
65 rpm
80 rpm
50 rpm
65 rpm
80 rpm
Cadence (rpm)
50.2
64.9
77.5
49.1
64.1
78.6
Total PO (W)
32.6
30.3
35.9
64.1
68.2
71.3
Absolute PO less
22.5
25.7
31.7
37.7
40.7
45.6
affected limb (W)
Absolute PO more
10.1
4.6
4.2
26.5
27.5
25.7
affected limb (W)
Relative PO less
69.0
85.2
88.5
58.7
59.7
64.0
affected limb (%)
Relative PO more
31.0
14.8
11.5
41.3
40.3
36.0
affected limb (%)
Asymmetry Index (%)
76.0
140.8
153.9
34.9
38.8
56.1
Note. PO = Power Output.

Table 5. Control participant 2 cycling performance and asymmetry data
Preferred PO
Fixed PO (60 W)
50 rpm
65 rpm
80 rpm
50 rpm
65 rpm
80 rpm
Cadence (rpm)
50.1
64.9
79.8
50.1
65.1
80.0
Total PO (W)
69.5
65.0
69.5
61.8
63.2
66.8
Absolute PO dominant
33.2
31.3
28.9
29.3
29.2
28.2
limb (W)
Absolute PO non36.3
33.7
40.6
32.5
34.0
38.6
dominant limb (W)
Relative PO dominant
47.9
48.6
41.5
47.5
46.2
42.2
limb (%)
Relative PO non52.1
51.4
58.5
52.5
53.8
57.8
dominant limb (%)
Asymmetry Index (%)
-8.5
-5.5
-34.0
-10.0
-15.0
-31.4
Note. PO = Power Output.
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Chapter IV
Discussion
The purpose of this study was to examine the effects of pedaling cadence on interlimb
asymmetry in crank power output in patients with PD compared to healthy controls. The limited
data collected support the first hypothesis that interlimb asymmetry is greater in individuals with
PD when compared to healthy age- and sex-matched controls. However, these data do not appear
to support the second hypothesis that interlimb asymmetry in pedaling power decreases at faster
pedaling cadences.
Data in the current study, although very small in sample size, support the hypothesis that
individuals with PD exhibit a greater degree of asymmetry in pedaling power compared to
healthy controls. In individuals with PD, clinical features such as resting tremors, bradykinesia,
rigidity, and postural imbalance are commonly more distinct on one side of the body compared
to the other 13. Asymmetries in the manifestation of PD could lead to one side of the body
contributing more force production than the other 12. It is common for up to 80% of individuals
affected by PD to experience one side of the body being more affected by the disease before the
disease becomes bilateral 12. This may be attributed to the reduction in movement sensation and
awareness of joint position, or proprioception, from the depression of dopamine production 35-36.
In the current study, the range of asymmetry in pedaling power output was between 34.9153.9% in individuals with PD compared to 1.0-34.0% in the healthy controls. These data are
similar to results found by Penko et al. 13, who also investigated symmetry in pedaling mechanics
for an incremental workload cycling test in individuals with PD. Penko et al. 13 reported
symmetry indices for average power output ranging from roughly 0.2-1.2. Note that in the
current study and that by Penko et al. 13, the index of symmetry was calculated identically except
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the index was presented as percentage in the current study, whereas Penko et al. 13 presented their
data as a ratio. So, dividing the index of symmetry values obtained in the current study by 100
will make the data be directly comparable to that reported by Penko and associates 13. Although
the degree of asymmetry in people with PD is similar in the current study compared to the study
by Penko et al. 13; in the current study, there was an experimental control of pedaling workload
and cadence whereas Penko et al. 13 did not directly control these parameters.
Interlimb asymmetry in effort appears to be a common observation across different motor
tasks for individuals with PD. These motor tasks include, but are not limited to, walking and
standing balance. Boonstra and colleagues 12 examined the effect of static standing perturbations
on postural stability and balance in individuals with PD and healthy individuals. They observed
that individuals with PD showed a greater degree of asymmetry in weight-bearing proportion and
balance-control contributions whereas the healthy controls distributed their weight more evenly
and equal amounts of torque were exerted by both legs 12. Yogev et al. 37 examined gait
asymmetry patterns in individuals with PD, elderly individuals with a history of falling, and
healthy controls. They observed a significantly higher degree of asymmetry in the individuals
with PD, followed by the elderly “fallers” when compared to the healthy controls. In summary,
interlimb asymmetry is a common manifestation of PD observed across different motor tasks
such as walking 37, standing balance 12, and cycling 13.
With respect to the second hypothesis (i.e. pedaling asymmetry decreases at faster
cadence), three of the four participants in the current study showed an opposite trend. For these
three participants when cycling at faster cadence, asymmetry in pedaling power increased. One
participant did not show a clear trend in pedaling power when cycling cadence systematically
became faster. In research done on young healthy cyclists, it was found that when pedaling
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faster, asymmetry became less pronounced 32, 38-39. Interlimb asymmetry is commonly observed
in healthy young recreational and competitive cyclists, and they exhibit a range from five to
twenty percent during cycling 38, yet these values decreased as cadenced increased from 40-120
rpm 32, 38-39. It is also prudent to note that a recent study reported that interlimb asymmetry is
unaffected by cadence as well as external workload in older healthy individuals and those with
knee osteoarthritis 34. Data from the current study and the other studies mentioned thus far 32, 34,
38-39

, show that young adults, older adults, and individuals with PD do not show consistent effect

of pedaling cadence on asymmetry of pedaling effort. One factor contributing to this
inconsistency in results, could be that participants in the current study and that by Buddhadev et
al. 34 did not cycle at higher cadences (50-90 rpm) compared to the studies with healthy, young
participants (40-110 rpm) 32, 38-39. Future studies should reexamine the effects of cadence in
individuals with PD using cadences higher than those used in the current study.
For individuals with PD, the investigation of the effect of pedaling cadence on cycling
performance (i.e. symmetry of effort) was important because therapeutic benefits of cycling are
only found at faster cadences. Ridgel et al. 9, 14 and Alberts and colleagues 20 observed that the
individuals who pedaled at faster cadences (80-90 rpm) when compared to slower cadences (6065 rpm) experienced an improvement in motor functions as well as an improvement in cortical
and motor response. This data suggests that in order to elicit a beneficial change in individuals
with PD, faster cadences are required.
One noteworthy strength of the current study was the use of both fixed workload (i.e. 60
W) and preferred, self-selected workload for assessment of interlimb asymmetry in pedaling
power. The analysis of asymmetry at a fixed workload exhibits high internal validity, because
Penko et al. 13 found that systematic increase in workload reduced asymmetry in pedaling power
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in patients with PD. Experimentally controlling pedaling workload provides a more precise
assessment of the effects of cadence on asymmetry because the confounding effects of pedaling
workload are removed. Conversely, assessment of asymmetry in pedaling power at self-selected
workload exhibits high external validity. Generally, when patients with PD pedal during their
training or rehabilitation sessions, they self-select the pedaling workload (i.e. resistance).
Limitations
An important limitation of the current study was the small sample size. The data
collection has not been completed for the study due to difficulty in recruiting individuals with
PD, especially under the age of 70 years. There is a need to collect more data to obtain an
adequate sample size, as estimated in the statistical power analysis. A descriptive analysis was
presented for the data collected thus far. However, with an adequate sample size, statistical
analysis can be performed to determine if data do or do not support the experimental hypotheses.
An important observation in the current study was that at higher pedaling power output
asymmetry in pedaling mechanics were lower in individuals with PD. For participants with PD,
the preferred pedaling power was lower (30.3-44.2 W) compared to the experimentally fixed
power output (60W). For the two participants with PD, a consistent trend of having lesser
asymmetry at higher power output was observed. At experimentally controlled power output (60
W), asymmetry ranged from 34.9-106.0 % whereas for the preferred power output condition,
asymmetry ranged from 76.0-153.9 % for both participants. These data suggest that asymmetry
decreases when the individual cycles at a power output greater than their self-selected
resistances. Penko et al. 13 did examine the effect of workload on asymmetry in crank power in
individuals with PD during an incremental test performed at self-selected cadence. They found
that with systematic increase in workload interlimb asymmetry reduced 13. However, prior
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research shows that cadence affects symmetry of pedal power 32, 38-39 and thus, there is a need to
examine the systematic effect of workload at fixed cadences on asymmetry in pedaling power.
Conclusion
Based on the limited data collected, participants with PD exhibit substantially greater
degree of asymmetry than healthy controls, and a systematic increase in cadence did not have an
effect on the degree of asymmetry in pedaling power output.
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Chapter V
Review of Pertinent Literature
Cycling at faster pedaling rates leads to symptomatic improvement in patients with
Parkinson’s disease (PD). However, these patients show inter-limb asymmetry in pedaling power
when cycling at their slower self-selected cadence. The effects of faster pedaling cadence on
symmetry of effort between limbs is unknown. This chapter will introduce the reader to relevant
information about PD, neurorehabilitation via cycling, assessment of symmetry in cycling, and
cycling cadence (a mechanical variable that affects both symptoms and symmetry in cycling).
This pertinent review of literature provides evidence to support the testing protocol and
procedures used in the current study.
Overview of Parkinson’s disease
Etiology
Parkinson’s disease (PD) is the second most common, progressive neuromuscular
condition, after Alzheimer’s disease, affecting more than 10 million individuals worldwide 1-3, 40.
Both the prevalence and the incidence of the disease increases with age. For individuals age 60
years or higher, the incidence of PD is 1-2% 40-41. Though the prevalence rates compared
between sexes has shown to be insignificant, more males have been reported to have the disease
40

, with incidence showing significance in the age range of 60-69 and 70-79 42. The exact cause

for the disease is unknown, but studies have shown that both genetic and environmental factors
play a role in the development of PD 40-41, 43-44.
Neurophysiology
Parkinson’s disease is characterized by changes in the brain, more specifically the basal
ganglia. The basal ganglia are a group of subcortical nuclei that are highly connected with many
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areas of the brain including the cortex, thalamus, and brain stem. These nuclei are associated
with many functions of life, including voluntary movement, cognition, and emotion. Synaptic
pathways between the basal ganglia and the cortical systems are affected by dopaminergic status,
and dysfunction in these connections may lead to Parkinson’s disease symptomology 5, 44.
Within the basal ganglia is a structure known as the substantia nigra, which plays a role
in movement and reward. Degeneration of the dopaminergic neurons within the substantia nigra
pars compacta leads to as much as a 90% reduction in dopamine in the striatum, depriving the
basal ganglia of the dopamine that it requires to initiate and facilitate movement and postural
control required of daily living. This deprivation leads to many of the motor and non-motor signs
and symptoms observed in PD 3, 6, 40, 43. de Lau et al. 1 speculated that dysfunction at the
muscular level, such as mitochondrial dysfunction, oxidative stress, and protein mishandlings,
may play a role in the pathogenesis of PD.
Symptomology
PD is characterized by motor and non-motor symptoms. As the disease progresses, it
becomes an increasing social and economic burden on those affected. Four cardinal motor
symptoms associated with PD are resting tremors, bradykinesia or akinesia, rigidity, and postural
imbalances. Resting tremors are an involuntary oscillatory movement produced when a limb is
fully supported against gravity and the muscles involved are not active 7. Bradykinesia or
akinesia are defined as a slowness or absence in movement initiation and execution. There is also
an observed reduction in the amplitude of movement up until complete cessation of the
movement 8. Diminished levels of dopamine and associated reduced motor control output in
patients with PD, is suggested to influence bradykinetic movements and impaired sensory
integration 9.
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Rigidity refers to an increase in resistance when passively stretching a muscle 10. As PD
progresses, patients begin to exhibit abnormal body posture, including an increase in flexion of
the head and cervical spine, an increase in thoracic kyphosis, and other postural imbalances that
greatly affect daily life 1, 11. Even though these symptoms are very common in patients with PD,
some of these symptoms are not always observed. The current criteria for the diagnosis of PD
includes the presence of at least two of these motor symptoms 1. The non-motor symptoms
include sensory deficits, insomnia, and emotional problems such as depression, lack of facial
expression, a slowing of gastrointestinal function, and reduction in the sense of smelling 45-46.
Diagnosis and Classification
Unified Parkinson’s Disease Rating Scale
Though there exists a paucity of reliable and valid tools for these assessments, the
Unified Parkinson’s Disease Rating Scale (UPDRS) has been widely used to assess many factors
of PD including activities of daily living (ADLs), motor symptoms, mentation, and treatment
complications in these patients 25-26. Ramaker et al. 25 reports high internal consistency, interrater reliability, and a moderate construct validity for this assessment. The UPDRS has specific
use in PD, covers many arrays of the widespread scope of PD in differing severities, as well as
clinimetric properties, especially in ADLs, and motor examination. In 2009, the release of the
Movement Disorder Society-UPDRS (MDS-UPDRS) improved on the older version of the test
to cover multiple groups at differing levels of severity 47. The MDS-UPDRS consists of four
parts: I: non-motor experiences of daily living; II: Motor experiences of daily living; III: Motor
examination; IV: Motor complications. Patient and caregiver or administrator complete questions
in each section on a rating scale of zero to four, with zero being normal, one being slight, two
being mild, three being moderate, and four being severe 48. The MDS-UPDRS rates sixty-five
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items, taking the patient and caregiver approximately thirty minutes to complete 48.
Hoehn and Yahr scale
The Hoehn and Yahr scale has been widely accepted and utilized in the research of PD 18,
49-50

. In a research setting, the Hoehn and Yahr scale is primarily used to define

inclusion/exclusion criteria 49. The scale consists of five stages, with each stage increasing in the
severity of the disease.
The modified Hoehn and Yahr scale is as follows: 47
Stage 0: No signs of disease
Stage 1.0: Symptoms are very mild; unilateral involvement only
Stage 1.5: Unilateral and axial involvement
Stage 2: Bilateral involvement without impairment of balance
Stage 2.5: Mild bilateral disease with recovery on pull test
Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent
Stage 4: Severe disability; still able to walk or stand unassisted
Stage 5: Wheelchair bound or bedridden unless aided
Pharmacological management with Levodopa
Since PD remains a progressive, and thus far, a non-curable disease, rehabilitation has
focused on decreasing the rate of progression as well as aiding in alleviating the side-effects that
are common from the debilitating disease. For nearly the past half century, the use of the drug
Levodopa (L-dopa) has been used to help alleviate the symptoms of PD 51. Further research
found that administration of L-dopa in lab animals led to an excretion of dopamine in the urine,
suggesting that dopamine levels were elevated 9, 51-52. Although, as the disease progresses,
complications arise from Levodopa use, including either inadequate dopaminergic tone, where
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the drug wears off or there are dose failures, or excessive dopaminergic tone that can cause
levodopa-induced dyskinesia 52. Though alternative medication can be used once L-dopa begins
to have these side-effects, alternative medication is generally only used once a tolerance to Ldopa develops 52.
Neurorehabilitation for PD
PD is identified as a dysfunction in sensorimotor integration, leading to common
symptoms such as bradykinesia and other atypical movement. Alternative rehabilitation methods
have been researched regarding how they can positively elicit changes in the symptoms observed
in PD 2-3, 8-9, 14. Neurorehabilitation programs are an increasingly favored method for the
rehabilitation of PD 53. Huang et al. 53 also stated since the mechanism for the symptoms of PD,
including weakness and fatigue, are unknown and often subjective, challenges arise when
constructing neurorehabilitation programs. Though exercise has shown to combat other sideeffects such as sleep deprivation and depression, finding a regimen that can improve kinesthetic
deficits as well can be difficult 17. Many studies have shown an increased attention to
interventions that promote changes in neural drive 9, 13. These studies have shown that an
increase in not just motor output, but sensory input may play a role in these motor improvements,
and since drugs like levodopa do not improve these kinesthetic deficits, neurorehabilitation
interventions like these are greatly needed 14. High intensity exercise has been highly suggested
as a method to increase neural drive and promote neural plasticity as well as neuroprotection
against dopaminergic cell loss 14. Though the exact method is still undetermined, non-invasive
trans-magnetic stimulation has been used to show a decrease in the dysfunction of corticomotor
excitability in people with PD 54. These changes in corticomotor excitability could be at the base
of symptomatic improvements.
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Neurorehabilitation through cycling
An increasing interest in cycling specifically has occurred in researchers studying the
effects of neurorehabilitation interventions for PD 16. Penko et al. 13 stated that pedaling is a
bipedal motor task, similar to walking, that requires the same principles of lower extremity
coordination, so quantifying pedaling kinetics can give a more precise measurement of lower
extremity function. The exact protocol for cycling has been studied largely by researchers hoping
to find a protocol that improves kinesthetic deficits the most 9, 13-14, 16. Alberts et al. 16 stated that
in order for the patients to gain a benefit from exercise, the rate of the exercise must be increased
to trigger a release of neurotrophic factors and possibly dopamine.
Mode of cycling
A wide array of protocols have been examined regarding cycling, and can be classified
into three distinct categories; Active, active-assisted, and passive. Active, also known as
voluntary cycling, is performed by the patient alone, usually at a self-selected pace 55. Granted,
individuals do see some improvements in symptomology from an active protocol, the other
modes of exercise have been shown to elicit greater improvements 9, 13-14, 16, 55. Active-assisted
cycling involves the individual biking with the assistance of an able-bodied individual on a
tandem bicycle. The exact mechanism for a greater response to active-assisted cycling is
unknown, however it is hypothesized that patients are cycling at a cadence faster than their
preferred speed, promoting an increase in afferent input to the central nervous system 56. The
hypotheses further states that during active-assisted cycling, sensory feedback coming from the
periphery along with subsequent activation of the basal ganglia circuits may be combatting the
abnormal motor output that is observed in individuals with PD 14. Ridgel et al. 14 found that
patients in an active-assisted group showed a 13% greater increase in UPDRS scores than
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compared to a voluntary group. In a practical sense, active-assisted cycling may not be the best
mode in terms of resources as well as at-home protocols. Not every individual will be able to
have an able-bodied assistant to help them during at-home sessions. Passive cycling, or forced
exercise (FE), has been researched to work around these limitations. During FE, the individual is
assisted through a motorized bike that is set at a specific cadence. Patients are told to cycle with
the cadence of the motorized bike, so it is not passive in the sense that the patient is not cycling,
but they do not need to exert the force required to increase the cadence past their comfortable
range 14, 16. It has been proposed that FE promotes angiogenesis and synaptogenesis, and for
individuals with PD the formation of new blood vessels and synapses within the brain decreases.
Acute aerobic exercise, in this case through a forced-cycling regimen, has been shown to release
neurotrophins such as brain-derived neurotrophic fact (BDNF) and glial-derived neurotrophic
factor (GDNF) as well as dopamine, which aids in supporting neuroplasticity as well as protect
against cell loss in the basal ganglia. The key to this difference between FE and VE is the
increase in intrinsic feedback, given by the faster pedaling rate 16.
Mechanical variables critical for cycling performance assessment
Cadence
The specific modality of the cycling training program has been extensively studied as to
which modality is the most beneficial, and there has been an increasing interest in speed-based
training. Uygur et al. 18 examined the effects of an acute cadence-derived protocol primarily on
the symptoms of bradykinesia in Parkinson’s disease patients. Three groups were included; no
exercise, voluntary cycling, and high cadence-low resistance (HC:LR) cycling. For the HC:LR
group, the cycled at a self-selected pace, similar to the voluntary group, but during the first 15seconds of minutes 5-24, they pedaled at a self-selected fast cadence. They found that subjects in
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the HC:LR group had significant improvement during a 4-square step test and 10-minute walk
test, primarily in walking velocity. It is suggested that this exercise facilitates locomotor central
pattern generators, which are generally impaired in the Parkinson’s disease population.
Power output
Pedaling power output from each leg is representative of that lower extremity’s effort and
it can be quantified using force-sensing pedals and trigonometric equations 23. In cycling
pedaling power outputs are therefore, commonly used for assessment of asymmetry between
limbs 13. During cycling, power output is representative of the total contribution of the lower
extremities, and a net power output can be maintained by reducing the output of one leg, and
correspondingly increasing the output of the other leg 22. Hunt and associates 23 examined
interlimb asymmetry in individuals with and without an anterior cruciate ligament (ACL) injury
while cycling and found that the individuals with ACL injuries demonstrated substantial
interlimb asymmetry (~50%). These individuals contributed significantly less with their injured
limb and compensated by increasing the power output of the ACL-intact limb. The authors
suggested the interlimb asymmetry observed in these individuals may compromise the
therapeutic benefits of cycling towards restoring strength in the limb post-injury.
Buddhadev et al. 34 also examined interlimb asymmetry in power output for individuals
with knee osteoarthritis and healthy controls. Their data showed that individuals with knee OA
demonstrated significant interlimb asymmetry (~10%) whereas healthy controls did not show
asymmetry. The interesting finding was individuals with knee OA were asymmetrical with their
more affected leg generating more power output than their less affected leg. This direction of
asymmetry is opposite to that observed for people with ACL injuries 23 and those with PD 13.
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Penko et al. 13 studied the effects that power output has on interlimb asymmetry in power
output in subjects with PD during an incremental cycling task. They tested their subjects by
having them cycle on a cycle ergometer beginning at 20W for three minutes at a self-selected
cadence. They then increased the power by 20W every two minutes until the fourth stage (eighth
minute), when 40W increases were made until exhaustion. A symmetry index was calculated to
determine whether the affected limb was contributing more or less as power increased. They
found that subjects with PD showed large interlimb asymmetry in power output. The more
affected side produced less power and as a compensation the less affected side correspondingly
increased its power output. They also reported a decrease in the symmetry index as workload
increased, indicating that symmetry was increasing. The results of their study helped support a
claim for a therapeutic intervention that provides higher quality and quantity afferent information
through the use of augmented pedaling motion, as seen in forced exercise.
Measurement of cycling and its importance in rehabilitation
Asymmetry
As PD progresses, individuals experience a decrease in gait function, postural stability,
and coordination of voluntary movements. Every human exhibits some degree of asymmetry that
mostly goes unnoticed throughout the gait cycle 57, but individuals with PD exhibit a greater
degree of asymmetry that affects their activities of daily living. With age, the increase in
asymmetry may also lead to injury. Portegijs 58 examined elderly healthy women, and elderly
women who sustained hip fractures. They introduced the women to an exercise protocol to
strengthen the lower limbs and found that with this protocol, the healthy group had a difference
in lower-limb power between limbs of an average of 15%. The injured group had significantly
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weaker injured limbs, but after the exercise protocol, an improvement of power led to decreases
in asymmetry and improvements in mobility.
During cycling, asymmetry can be directly quantified by measuring the crank power
output of a modified cycle ergometer 13. Identifying asymmetry in Parkinson’s disease patients
would therefore provide a baseline to be later used to measure the effectiveness of an
intervention 13. Also, identification of the limb that is contributing less to the overall power
output can lead to training regimens focused on strengthening the said limb, or reducing the
degree of asymmetry.32 One of the primary goals of exercise regimens for individuals with PD
should be reducing asymmetry, thus improving symmetry during normal daily activity. Most
healthy individuals exhibit a degree of asymmetry between 5-20% 38, but as the degree of this
asymmetry increases, detrimental outcomes such as risk of injury increases 31.
Asymmetry has been examined in individuals with other lower limb conditions such as
anterior knee pain and knee osteoarthritis across different physical activities. Radin et al. 59
examined lower limb kinetics and kinematics in individuals with activity-related knee pain and
asymptomatic subjects. They observed significant differences in heel strike and angular velocity
in the individuals with knee pain. They suggested that these observations lead to future damage if
not corrected. Buddhadev et al. 34 examined the effects of pedaling power and cadence on
interlimb asymmetry in individuals with knee OA. They observed a significant difference in the
contribution to total power from each limb. The more affected limb contributed a higher power
output than the less affected limb, which according to these authors could limit the efficacy of a
rehabilitative process.
Index of asymmetry
Researchers have used the Symmetry Index as a method of evaluating the degree of
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interlimb asymmetry in different populations. For example, Penko et al. 13 calculated the
symmetry index using the equation below:
𝑺𝒚𝒎𝒎𝒆𝒕𝒓𝒚 𝑰𝒏𝒅𝒆𝒙 (𝑺𝑰) =

Unaffected limb − Affected limb
(Unaffected limb + affected limb)/2

Using this equation, the researchers could evaluate the degree of contribution from each limb,
with a positive value indicating a greater contribution by the unaffected limb, and a negative
number indicating a greater contribution from the affected limb 13. These variables could be
modified to evaluate left versus right leg contribution.
Other methods have been used for analyzing interlimb asymmetry by researchers
Buddhadev et al. 34 and Hunt et al. 23. Buddhadev et al. 34 reported the two asymmetry indices for
the individuals with knee osteoarthritis and healthy controls, respectively:
𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝐼𝑛𝑑𝑒𝑥 (%) =

𝐿𝑒𝑠𝑠 𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑒𝑔 𝑝𝑜𝑤𝑒𝑟 − 𝑀𝑜𝑟𝑒 𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑙𝑒𝑔 𝑝𝑜𝑤𝑒𝑟
x 100
Less affected leg power

𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝐼𝑛𝑑𝑒𝑥 (%) =

Dominant leg power − Nondominant leg power
x 100
Dominant leg power

Similarly, Hunt et al. 23 calculated interlimb asymmetry as a ratio using the equation below:
𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 𝐼𝑛𝑑𝑒𝑥 =

𝑎
− 1
b

Where a was the mean power output from either the right limb of the uninjured subject, or the
ACL of the intact limb for the injured subject, and b was the mean power output of the left limb
of the uninjured subject, or the ACL-deficient limb of the injured subjects.
Many different equations exist for the representation of asymmetry, however for the
current study, the method utilized by Penko et al. 13 was used because the current study is
examining the same population (i.e. individuals with PD) for the same mechanical task (i.e.
stationary cycling) as these authors.
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Summary
In this review of literature, important gaps in the research relevant to interlimb
asymmetry in pedaling performance in patients with PD have been identified. In addition, this
systematic review also explored the mechanisms underlying asymmetry in this population and
methods used to evaluate interlimb asymmetry.
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Appendix A
Western Washington University
Health and Human Development Department
Consent to Take Part in a Research Study
Project: Does cycling speed affect leg asymmetry in pedaling power in individuals with
Parkinson’s disease?
You are invited to participate in a study investigating the effects of pedaling speed on how
evenly you are pushing the pedal with each leg in individuals with or without Parkinson’s
disease (PD). Previous research has shown that cycling at faster cadences benefits individuals
with PD. Despite these known benefits of cycling, little to no research has addressed the effect of
cadence on interlimb asymmetry in individuals with PD.
If you agree to participate in this study, you will complete one testing session lasting 45 minutes
to one hour. If you have PD, you will need to visit a local neurologist for diagnostic purposes
when you are off your PD medication for 12 hours. After this visit, you will complete the single
testing session. You are asked not to perform any exhausting lower body exercises within 48
hours prior to the testing session.
I UNDERSTAND THAT:
1. The testing session at Western Washington University will begin with completing the
informed consent document. I will also complete a health history and physical health
questionnaire to help researchers confirm that I qualify for their project.
2. My height and weight will be measured using a stadiometer and balance beam scale,
respectively.
3. I will wear cycling shoes provided by the investigators. These shoes allow the researchers
to clip them into the pedals.
4. Next the seat height, seat front-back adjustment, and handle position on the stationary
bicycle ergometer will be adjusted following standard bike fitting guidelines.
5. I will then perform a 5-minute warm-up at a low workload and comfortable pedaling rate.
6. Next, I will complete six workload-cadence combinations that form the six test
conditions for the experiment: (This is the equivalence of approximately 9 mph)
a. Self-selected pedaling resistance at 50 rpm
b. Self-selected pedaling resistance at 65 rpm
c. Self-selected pedaling resistance at 80 rpm
d. 60 Watts resistance at 50 rpm
e. 60 Watts resistance at 65 rpm
f. 60 Watts resistance at 80 rpm.
7. I will pedal for 3 minutes under each condition. I will be given a rest of 3-5 minutes
between trials, but if needed, I can rest longer than 5 minutes between trials.
8. As I pedal under these experimental conditions, the researchers will collect data from the
force pedals which will later be entered into I-Crankset software to examine my pedaling
mechanics.
9. I will then perform a 5-minute cool down at a low workload and comfortable pedaling
rate.
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10. If I have PD, I will visit a local neurologist (Dr. Bruce Mackay) to assess the stage of the
disease within 4-weeks after the testing sessions at Western. This will be a free session. I
will be off PD medication for 12 hours prior to this free session. Being off medication for
this time may cause the effects of the medication to wear off some and thus, make the
symptoms of PD more apparent. Hence, I may experience some mild aggravation of my
PD symptoms. I understand that exercise can lead to fatigue and muscular and/or joint
discomfort or pain. Rest intervals that follow each cycling trials should reduce fatigue. I
understand that if at any point exercise testing becomes uncomfortable, I can stop at any
time. If I feel like I cannot or should not perform any of these tasks, I could opt out from
the participation in this study.
11. I understand that there may be a risk of falling and if I have any undiagnosed cardiac
conditions, this may trigger cardiovascular events. I understand that the researchers will
be standing by near the bicycle at all times and observing me as I exercise.
12. In the event of an injury, I understand the study will be stopped immediately and
appropriate first aid will be given by the researcher.
13. By participating in this research study, I could gain knowledge about my pedaling
asymmetry. In addition, the results of this study may aid in future research.
14. All information collected will be kept in a locked cabinet separate from the data
collection forms for the project data. My name will not be associated with any of my data
collected throughout the study. These data will be labeled with an ID number and
separate list connects the ID number and my identifiers. The data with the ID numbers
and separate lists will be stored in different secure locked cabinets in the Applied
Neuromechanics research laboratory in the Carver Academic Facility.
15. I may choose not to participate in this study. I am free to withdraw at any time, without
penalty. If I withdraw from the study, the researchers will retain the data collected up
until that point. I may submit a request to the researchers to withdraw my data up until
the study ends. After the study ends, the researchers will not be able to link me with my
data.
16. I must be 18 years or older to participate
17. I understand that the link between my name and my study ID will be removed when the
researchers have completed analyzing the data.
18. My signature on this form does not waive my legal rights of protection.
19. Any questions you I have regarding the study procedures will be answered by the primary
researchers (Gary Wiley, Harsh Buddhadev) who can be contacted at wileyg@wwu.edu
(360-441-4248) or Harsh.Buddhadev.wwu.edu (360-650-4115). Any questions about
my rights as a research subject should be directed to the WWU Office of Research and
Sponsored Programs (RSP) at compliance@wwu.edu or (360) 650-2146. . If any injury
or adverse effect of this research is experienced I should contact Gary Wiley, Harsh
Buddhadev, or the RSP.

I have read the above descriptions and agree to participate in this study.
_______________________________________
Participant’s Signature
_______________________________________
Participant’s PRINTED NAME
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_____________________
Date

Appendix B
Western Washington University
Health and Human Development Department
Consent to Take Part in a Research Study
Project: Does cycling speed affect asymmetry in pedaling effort between legs in people with
Parkinson’s disease?
You are invited to participate in a study examining the effects of pedaling speed on how evenly
you are pushing the pedal with each leg in individuals with or without Parkinson’s disease (PD).
Previous research has shown that cycling at faster speeds benefits people with PD. Despite these
known benefits of cycling, little to no research has addressed the effect of cycling speed on
unevenness in pedaling effort between legs in individuals with PD.
If you agree to participate in this study, you will complete one testing session lasting 60 to 90
minutes. You are asked not to perform any tiring lower body exercises within 48 hours before
the testing session.
I UNDERSTAND THAT:
1. The testing session at Western Washington University will begin with completing the
informed consent document. I will also complete a health history and physical health
questionnaire to help researchers confirm that I qualify for their project.
2. My height and weight will be measured.
3. I will wear cycling shoes provided by the researchers. These shoes allow the researchers
to clip them into the pedals.
4. Next the stationary cycle will be adjusted according to my body size.
5. I will then perform a 5-minute warm-up at a low resistance and comfortable speed.
6. Next, I will complete six speed-resistance combinations that form the six test conditions
for the study:
a. Self-selected pedaling resistance at 50 rpm
b. Self-selected pedaling resistance at 65 rpm
c. Self-selected pedaling resistance at 80 rpm
d. 60 Watts resistance at 50 rpm
e. 60 Watts resistance at 65 rpm
f. 60 Watts resistance at 80 rpm.
(60 W is the equivalence of approximately 9 mph)
7.

I will pedal for 3 minutes under each condition. I will be given a rest of 3-5 minutes
between trials, but if needed, I can rest longer than 5 minutes between trials.
8. As I pedal under these conditions, the researchers will collect data from the force pedals
which will measure the unevenness in pedaling effort between legs.
9. I will then perform a 5-minute cool down at a low resistance and comfortable speed.
10. I understand that there may be a risk of falling and if I have any undiagnosed cardiac
conditions, this may trigger heart conditions. I understand that the researchers will be
standing by near the stationary cycle at all times and observing me as I exercise.
11. In the event of an injury, I understand the study will be stopped immediately and
appropriate first aid will be given by the researcher.
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12. By participating in this research study, I could gain knowledge about my pedaling
unevenness. In addition, the results of this study may help in future research.
13. All information collected will be kept in a locked cabinet separate from the data
collection forms for the project data. My name will not be associated with any of my data
collected throughout the study. These data will be labeled with an ID number and
separate list connects the ID number and my identifiers. The data with the ID numbers
and separate lists will be stored in different secure locked cabinets in the research
laboratory in the Carver Building.
14. I may choose not to participate in this study. I am free to withdraw at any time, without
penalty. If I withdraw from the study, the researchers will retain the data collected up
until that point. I may submit a request to the researchers to withdraw my data up until
the study ends. After the study ends, the researchers will not be able to link me with my
data. I understand that the link between my name and my study ID will be removed by
August 2019.
15. I must be 18 years or older to participate
16. My signature on this form does not waive my legal rights of protection.
17. Any questions you I have regarding the study procedures will be answered by the primary
researchers (Gary Wiley, Harsh Buddhadev) who can be contacted at wileyg@wwu.edu
(360-441-4248) or Harsh.Buddhadev.wwu.edu (360-650-4115). Any questions about
my rights as a research subject should be directed to the WWU Office of Research and
Sponsored Programs (RSP) at compliance@wwu.edu or (360) 650-2146. If any injury or
adverse effect of this research is experienced I should contact Gary Wiley, Harsh
Buddhadev, or the RSP.

I have read the above descriptions and agree to participate in this study.
_______________________________________
Participant’s Signature
_______________________________________
Participant’s PRINTED NAME
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_____________________
Date

